Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers

This publication has 66 references indexed in Scilit:

• Identification of the molecular basis of doxorubicin-induced cardiotoxicity
  Nature Medicine, 2012
• Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
  Circulation: Cardiovascular Imaging, 2012
• Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients
  British Journal of Cancer, 2011
• Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide
  International Journal of Cardiology, 2011
• Neuregulin-1β Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure
  Circulation, 2009
• Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
  Journal of Cancer Research and Clinical Oncology, 2008
• N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?
  Clinical Chemistry, 2005
• Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
  Circulation, 2004
• Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
  Journal of Clinical Oncology, 2004
• Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
  JACC, 2000